meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 1

anticoagulant, curative dose 1

anticoagulant, pre-admission 3

anticoagulant, prophylactic dose 2

sulodexide

face mask

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

colchicine 1

non-steroidal anti-inflammatory drugs 4

Ibuprofen 1

corticosteroids 1

Immunostimulants drugs

convalescent plasma treatment

interferon

IFN beta-1a

levamisole

neutralizing antibody

casirivimab/imdevimab (Ronapreve) 1

Immunosuppressants drugs

anti-interleukin-6

tocilizumab 1

statins

antiandrogenic

5-alpha-reductase inhibitors

antiviral and associated therapy

azithromycin

bromhexine

chloroquine and derivatives

chloroquine

hydroxychloroquine

doxycycline

favipiravir

fluvoxamine

hydroxychloroquine plus macrolides

ivermectin 1

lopinavir/ritonavir

zinc 1

Drugs for acid related disorders

proton pump inhibitors (PPI) 3

miscellaneous

2-deoxy-D-glucose (2-DG)

acetylcysteine

calcium channel blocker

kinin-kallikrein inhibitors

nicotin

ozonated autohemotherapy

radiotherapy

Oral antidiabetic drugs

DPP-4 inhibitor

metformin

Renin-angiotensin-system-acting agents 1

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs)

vaccines

BCG vaccination

DNA vaccine

bacTRL-Spike

Vitamins

vitamin C

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons